Smoking Cessation - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 100 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Smoking Cessation - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Smoking Cessation - Pipeline Review, H2 2014', provides an overview of the Smoking Cessation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Smoking Cessation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Smoking Cessation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Smoking Cessation Overview 9
Therapeutics Development 10
Pipeline Products for Smoking Cessation - Overview 10
Pipeline Products for Smoking Cessation - Comparative Analysis 11
Smoking Cessation - Therapeutics under Development by Companies 12
Smoking Cessation - Therapeutics under Investigation by Universities/Institutes 14
Smoking Cessation - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Smoking Cessation - Products under Development by Companies 18
Smoking Cessation - Products under Investigation by Universities/Institutes 19
Smoking Cessation - Companies Involved in Therapeutics Development 20
AllTranz, Inc. 20
Aradigm Corporation 21
Arena Pharmaceuticals, Inc. 22
Astraea Therapeutics, LLC 23
BIOPROJET SCR 24
Embera NeuroTherapeutics, Inc. 25
FORUM Pharmaceuticals Inc. 26
GlaxoSmithKline plc 27
Invion Limited 28
Johnson & Johnson 29
Marinus Pharmaceuticals, Inc. 30
NAL Pharmaceuticals Ltd. 31
Pfizer Inc. 32
Royalty Pharma 33
Selecta Biosciences, Inc. 34
Targacept, Inc. 35
TRIA Bioscience Corp. 36
Smoking Cessation - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
(oxazepam + metyrapone) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Anatabine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ARD-1600 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BP-1.4979 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
encenicline hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ganaxolone - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GSK-598809 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
lorcaserin hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
nadolol - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
NIC7-DT - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
nicotine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
nicotine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Nicotine Vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PF-05402536 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
PF-06413367 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SEL-068 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule for Smoking Cessation - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule to Agonize Alpha 4, Beta 2 and Alpha 6 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Smoking Cessation - Recent Pipeline Updates 78
Smoking Cessation - Dormant Projects 90
Smoking Cessation - Discontinued Products 91
Smoking Cessation - Product Development Milestones 92
Featured News & Press Releases 92
Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform 92
May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50% 92
Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial 93
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 94
Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs 95
Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint 95
Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation 96
Jan 12, 2012: Inverseon Focuses On Smoking Cessation As Initial Indication For INV102 97
Nov 21, 2011: Selecta Biosciences Initiates Phase I Clinical Study Of SEL-068 97
Oct 01, 2010: Embera NeuroTherapeutics' Lead Candidate, EMB-001, Supported by $3.9M Grant from National Institute on Drug Abuse 98
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100

List of Tables
Number of Products under Development for Smoking Cessation, H2 2014 10
Number of Products under Development for Smoking Cessation - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Comparative Analysis by Unknown Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Smoking Cessation - Pipeline by AllTranz, Inc., H2 2014 20
Smoking Cessation - Pipeline by Aradigm Corporation, H2 2014 21
Smoking Cessation - Pipeline by Arena Pharmaceuticals, Inc., H2 2014 22
Smoking Cessation - Pipeline by Astraea Therapeutics, LLC, H2 2014 23
Smoking Cessation - Pipeline by BIOPROJET SCR, H2 2014 24
Smoking Cessation - Pipeline by Embera NeuroTherapeutics, Inc., H2 2014 25
Smoking Cessation - Pipeline by FORUM Pharmaceuticals Inc., H2 2014 26
Smoking Cessation - Pipeline by GlaxoSmithKline plc, H2 2014 27
Smoking Cessation - Pipeline by Invion Limited, H2 2014 28
Smoking Cessation - Pipeline by Johnson & Johnson, H2 2014 29
Smoking Cessation - Pipeline by Marinus Pharmaceuticals, Inc., H2 2014 30
Smoking Cessation - Pipeline by NAL Pharmaceuticals Ltd., H2 2014 31
Smoking Cessation - Pipeline by Pfizer Inc., H2 2014 32
Smoking Cessation - Pipeline by Royalty Pharma, H2 2014 33
Smoking Cessation - Pipeline by Selecta Biosciences, Inc., H2 2014 34
Smoking Cessation - Pipeline by Targacept, Inc., H2 2014 35
Smoking Cessation - Pipeline by TRIA Bioscience Corp., H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Assessment by Combination Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 40
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Smoking Cessation Therapeutics - Recent Pipeline Updates, H2 2014 78
Smoking Cessation - Dormant Projects, H2 2014 90
Smoking Cessation - Discontinued Products, H2 2014 91